Hansa Biopharma intends to carry out a 10m Directed share issue executed by an accelerated book building. The directed share issue is part of a debt restructuring process with NovaQuest. This debt restructuring has already advanced, and in this first stage, Hansa Biopharma has secured growth funding for the ongoing launch activities, general opex and beyond two key phase 3 readouts into 2026. We expect a distinct positive price reaction on 19 June.
LÄS MER
